Study on Acupuncture Treatment of Chronic Airway Diseases(Asthma and Chronic Obstructive Pulmonary Disease)
Study on the Efficacy and Mechanism of Acupuncture in the Acute Stage of Chronic Airway Diseases (Asthma and Chronic Obstructive Pulmonary Disease)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yang Xie, Professor
- Phone Number: 13526621325
- Email: xieyanghn@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Meets the diagnostic criteria for acute attack of asthma/AECOPD;
- Age range from18 years to 80 years(asthma) and 40 yesrs to 80 years(COPD);
- The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form.
Exclusion Criteria:
- Patients with combined pulmonary abscess, pulmonary interstitial fibrosis, active pulmonary tuberculosis, bronchiectasis and other pulmonary diseases;
- Patients with severe cardiovascular and cerebrovascular diseases (such as malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, grade 3 or above cardiac function, stroke, cerebral hemorrhage, etc.);
- Patients with severe liver diseases (such as liver cirrhosis, portal hypertension and bleeding caused by esophageal and gastric fundus varices) and severe kidney diseases (such as dialysis, kidney transplantation, etc.);
- Patients with impaired consciousness or various mental disorders who are unable to communicate normally;
- Pregnant and lactating women;
- Those who are currently participating in other clinical trials within 1 month before enrollment;
- Patients with contraindications to acupuncture (such as severe allergic or infectious skin diseases);
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Acupuncture group for Asthma Acute/AECOPD
Patients in the Asthma Acute/AECOPD experimental group were treated with Acupuncture
|
Dingchuan, Shanzhong, Tiantu, Feishu, Kongji, after obtaining qi, connect the electric needle (continuous wave, The frequency was 2Hz, the current intensity was 1~5mA, and the current intensity was gradually increased according to patient tolerance), and the treatment was 30min.
|
|
Sham Comparator: Sham Acupuncture group for Asthma Acute/AECOPD
Patients in the Asthma Acute/AECOPD experimental group were treated with Sham Acupuncture
|
Dingchuan, Shanzhong, Tiantu, Feishu, hole the most points open 5~10mm, shallow piercing through the skin, connected with the electric needle but no electricity, treatment 30min.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Astham part: PEF
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
Record the peak expiratory flow rate(PEF) for each patient, and evaluate the impact of acupuncture on improving the peak expiratory flow (PEF) of asthma patients.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
|
COPD part:CTA
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
Record the COPD Assessment Test (CAT) for each patient, and evaluate the impact of acupuncture on improving the clinical symptoms of patients with AECOPD.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Astham part: the Asthma Control Test (ACT)
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
ACT includes five questions.
Every question will be assessed using a 5-point scale with scores ranging from 5 to 25.
The higher the score, the better the symptom control.25 is considered complete control level, 20 ~ 24 is considered good control level, and <20 is considered non-control level.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
|
Asthma part:Asthma Control Questionnaire(ACQ)
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
The content of ACQ involves the following aspects: asthma-related, symptoms, the use of first-aid drugs, the impact on daily life and lung function test results.The higher the score, the worse the state.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
|
Asthma part:Asthma Quality of Life Questionnaire(AQLQ)
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
The asthma quality of life scale (5-point scale-RRB- consists of 35 items, including activity limitation (1-12) , asthma symptoms (13-20) , psychological status (22-26) , response to stimuli (27-31) , concern for one's own health (32-35) .
On a 5-point scale, 1 is the worst and 5 is the best.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
|
Asthma part:The cough and expectoration assessment questionnaire (CASA-Q)
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
Each indicator of the patient is scored from 1 to 5 based on the severity.
After reverse scoring, the lower the score, the more severe the airway mucus hypersecretion and the poorer the therapeutic effect.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
|
Asthma part:Evaluation of Airway Mucus Hypersecretion
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
The assessment includes: the difficulty of expectoration score, the sputum character score, and the sputum viscosity grading.
They represent the nature of the sputum and the difficulty of coughing, ranging from 0 to 3 points.
The higher the score, the more mucus secretion in the airway and the more severe the symptoms.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
|
Asthma part:Evaluation of Airway Mucus by CT Imaging
Time Frame: Before treatment, and day 7
|
Airway mucus CT assessment evaluates the distribution characteristics of airway mucus through the imaging features of thin-layer CT.
|
Before treatment, and day 7
|
|
Asthma part:Clinical symptom score
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
Including wheezing, coughing, expectoration, chest tightness and wheezing sounds.A score of 0-3 will be given to every symptom or sign with a higher score indicating a worse conditoin.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
|
Asthma part:Acute attack status
Time Frame: Follow-up at the 4th and 13th weeks
|
Including the number and severity of acute attacks, the re-admission rate after acute attacks, and the interval between the first acute attack and the subsequent ones.
|
Follow-up at the 4th and 13th weeks
|
|
Asthma part:Hospitalization time
Time Frame: At 4 weeks of follow-up
|
The time required from the point of enrollment to the attainment of the discharge criteria
|
At 4 weeks of follow-up
|
|
Asthma part:Fractional exhaled nitric oxide (FeNO)
Time Frame: Before treatment, and day 7
|
FeNO is measured by a FeNO detector.
It is used to determine the concentration of nitric oxide in exhaled breath of the human body.
As a biomarker of airway inflammation, its normal range is less than 25ppb (adults) .
|
Before treatment, and day 7
|
|
COPD part:clinical symptoms and signs questionnaire
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
Assessment will be performed by clinical symptoms and signs questionnaire.
The clinical symptoms to be evaluated in this study include cough, phlegm, chest tightness, gasp,shortness of breath, feeble and cyanosis.
A score of 0-3 will be given to every symptom or sign with a higher score indicating a worse conditoin.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
|
COPD part:mMRC
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
The modified Medical Research Council (mMRC) scale is a 5-point (0-4) scale based on the severity of dyspnoea.
"0" means no dyspnea perception, "4" means severe dyspnea perception.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
|
COPD part:The cough and expectoration assessment questionnaire (CASA-Q)
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
Each indicator of the patient is scored from 1 to 5 based on the severity.
After reverse scoring, the lower the score, the more severe the airway mucus hypersecretion and the poorer the therapeutic effect.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
|
COPD part:Evaluation of Airway Mucus Hypersecretion
Time Frame: Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
The assessment includes: the difficulty of expectoration score, the sputum character score, and the sputum viscosity grading.
They represent the nature of the sputum and the difficulty of coughing, ranging from 0 to 3 points.
The higher the score, the more mucus secretion in the airway and the more severe the symptoms.
|
Before treatment, at 4 and 7 days of treatment, and at 4 and 13 weeks of follow-up
|
|
COPD part:Evaluation of Airway Mucus by CT Imaging
Time Frame: Before treatment, and day 7
|
Airway mucus CT assessment evaluates the distribution characteristics of airway mucus through the imaging features of thin-layer CT.
|
Before treatment, and day 7
|
|
COPD part:Acute attack status
Time Frame: Follow-up at the 4th and 13th weeks
|
The number of acute attacks
|
Follow-up at the 4th and 13th weeks
|
|
COPD part:Hospitalization time
Time Frame: At 4 weeks of follow-up
|
The time required from the point of enrollment to the attainment of the discharge criteria
|
At 4 weeks of follow-up
|
|
COPD part:Tracheal intubation rate
Time Frame: At 4 weeks of follow-up
|
The proportion of patients with tracheal intubation during the treatment period;
|
At 4 weeks of follow-up
|
|
COPD part: Arterial blood gas
Time Frame: Before treatment, and day 7
|
The arterial blood PaO2, PaCO2 of the two groups of subjects were measured.
|
Before treatment, and day 7
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Suyun Li, Professor, First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TCM for Chronic Airway Disease
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.